Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth

作者：Mukhopadhyay Archana^*; Hanold Laura E; Purayil Hamsa Thayele; Gisemba Solomon A; Senadheera Sanjeewa N; Aldrich Jane V^*

来源：Cancer Biology and Therapy, 2017, 18(8): 571-583.

DOI：10.1080/15384047.2017.1345384

• Prostate cancer
• c-Myc
• macrocyclic tetrapeptides
• CJ-15
• 208
• [D-Trp]CJ-15
• 208
• apoptosis
• cell cycle arrest

The oncoprotein c-Myc is often overexpressed in cancer cells, and the stability of this protein has major significance in deciding the fate of a cell. Thus, targeting c-Myc levels is an attractive approach for developing therapeutic agents for cancer treatment. In this study, we report the anti-cancer activity of the macrocyclic peptides [D-Trp]CJ-15,208 (cyclo[Phe-D-Pro-Phe-D-Trp]) and the natural product CJ-15,208 (cyclo[Phe-D-Pro-Phe-Trp]). [D-Trp]CJ-15,208 reduced c-Myc protein levels in prostate cancer cells and decreased cell proliferation with IC50 values ranging from 2.0 to 16 mu M in multiple PC cell lines. [D-Trp]CJ-15,208 induced early and late apoptosis in PC-3 cells following 48hours treatment, and growth arrest in the G2 cell cycle phase following both 24 and 48hours treatment. Down regulation of c-Myc in PC-3 cells resulted in loss of sensitivity to [D-Trp]CJ-15,208 treatment, while overexpression of c-Myc in HEK-293 cells imparted sensitivity of these cells to [D-Trp]CJ-15,208 treatment. This macrocyclic tetrapeptide also regulated PP2A by reducing the levels of its phosphorylated form which regulates the stability of cellular c-Myc protein. Thus [D-Trp]CJ-15,208 represents a new lead compound for the potential development of an effective treatment of prostate cancer.

• 出版日期2017